Literature DB >> 19249018

Vascular endothelial growth factor-induced chemotaxis and IL-10 from T cells.

Jin-Young Shin1, Il-Hee Yoon, Jung-Sik Kim, Bongi Kim, Chung-Gyu Park.   

Abstract

Vascular endothelial growth factor (VEGF) is a proangiogenic mediator that promotes tumor growth. The role of VEGF in T lymphocytes is unknown. We found that T lymphocytes activated by either anti-CD3 monoclonal antibody (mAb) plus anti-CD28 mAb or by antigens on antigen-presenting cells transcribed mRNA for VEGF receptor 1 (VEGFR1) and VEGFR2. However, only VEGFR1 was expressed on the T cell surface. The addition of VEGF to either resting or activated T cells did not affect their proliferation, but VEGF increased IL-10 production and slightly decreased IFN-gamma production. A chemotaxis assay revealed that activated T lymphocytes migrate in response to VEGF. Our data suggest that VEGF has a direct immunomodulatory effect on T cells. Engagement of a high concentration of VEGF with VEGFR1 on T cells may cause T cells to migrate to tumor sites, and this interaction may play a role in IL-10-mediated immune evasion by tumor cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19249018     DOI: 10.1016/j.cellimm.2009.01.006

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  23 in total

1.  Effect of vascular endothelial growth factor and its receptor KDR on the transendothelial migration and local trafficking of human T cells in vitro and in vivo.

Authors:  Monika Edelbauer; Dipak Datta; Ingrid H C Vos; Aninda Basu; Maria P Stack; Marlies E J Reinders; Masayuki Sho; Katiana Calzadilla; Peter Ganz; David M Briscoe
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

2.  VEGF blockade inhibits lymphocyte recruitment and ameliorates immune-mediated vascular remodeling.

Authors:  Jiasheng Zhang; Teresa Silva; Timur Yarovinsky; Thomas D Manes; Sina Tavakoli; Lei Nie; George Tellides; Jordan S Pober; Jeffrey R Bender; Mehran M Sadeghi
Journal:  Circ Res       Date:  2010-06-10       Impact factor: 17.367

3.  CD4+VEGFR1(HIGH) T cell as a novel Treg subset regulates inflammatory bowel disease in lymphopenic mice.

Authors:  Jin-Young Shin; Il-Hee Yoon; Jong-Hyung Lim; Jun-Seop Shin; Hye-Young Nam; Yong-Hee Kim; Hyoung-Soo Cho; So-Hee Hong; Jung-Sik Kim; Won-Woo Lee; Chung-Gyu Park
Journal:  Cell Mol Immunol       Date:  2015-07-27       Impact factor: 11.530

4.  The parallel lives of angiogenesis and immunosuppression: cancer and other tales.

Authors:  Gregory T Motz; George Coukos
Journal:  Nat Rev Immunol       Date:  2011-09-23       Impact factor: 53.106

5.  Immune cells regulate VEGF signalling via release of VEGF and antagonistic soluble VEGF receptor-1.

Authors:  T Hoeres; M Wilhelm; M Smetak; E Holzmann; G Schulze-Tanzil; J Birkmann
Journal:  Clin Exp Immunol       Date:  2018-01-04       Impact factor: 4.330

Review 6.  Cancer immunotherapy comes of age.

Authors:  Ira Mellman; George Coukos; Glenn Dranoff
Journal:  Nature       Date:  2011-12-21       Impact factor: 49.962

7.  Cutting edge: Vascular endothelial growth factor-mediated signaling in human CD45RO+ CD4+ T cells promotes Akt and ERK activation and costimulates IFN-gamma production.

Authors:  Aninda Basu; Andre Hoerning; Dipak Datta; Monika Edelbauer; Maria P Stack; Katiana Calzadilla; Soumitro Pal; David M Briscoe
Journal:  J Immunol       Date:  2009-12-11       Impact factor: 5.422

8.  Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer.

Authors:  Christina L Roland; Kristi D Lynn; Jason E Toombs; Sean P Dineen; D Gomika Udugamasooriya; Rolf A Brekken
Journal:  PLoS One       Date:  2009-11-03       Impact factor: 3.240

9.  CD47 signaling regulates the immunosuppressive activity of VEGF in T cells.

Authors:  Sukhbir Kaur; Tiffany Chang; Satya P Singh; Langston Lim; Poonam Mannan; Susan H Garfield; Michael L Pendrak; David R Soto-Pantoja; Avi Z Rosenberg; Shelly Jin; David D Roberts
Journal:  J Immunol       Date:  2014-09-08       Impact factor: 5.422

Review 10.  An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma.

Authors:  David A Reardon; Kai W Wucherpfennig; Gordon Freeman; Catherine J Wu; E Antonio Chiocca; Patrick Y Wen; William T Curry; Duane A Mitchell; Peter E Fecci; John H Sampson; Glenn Dranoff
Journal:  Expert Rev Vaccines       Date:  2013-06       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.